Beam Therapeutics Inc. (BEAM): Capital Expenditures
$14.95M
Year ended 2025-12-31
$13.39M
Trailing 12 months to 2026-06-30
-32.7%
3-year compound annual growth
-1.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.95M | +67.1% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $8.95M | -73.5% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $33.73M | -31.1% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $48.95M | +4.6% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $46.81M | +186.2% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $16.36M | +30.7% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $12.52M | n/a | 2022-02-28, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $14.95M | +67.1% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $4.70M | +17.9% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $0 | -100.0% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $7.67M | -87.7% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $2.41M | -0.9% |
| Agenus Inc (AGEN) | 2025-12-31 | $6.0K | -99.0% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $3.85M | -44.2% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $886.0K | -81.1% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $848.0K | +450.6% |
Compare BEAM, GLUE, ATRA, DNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗